 Rachel Miller
Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 19 | 2020 | 369 | 6.920 |
Why?
| | Arthralgia | 6 | 2020 | 120 | 3.920 |
Why?
| | Pain | 9 | 2020 | 336 | 3.030 |
Why?
| | Osteoarthritis, Knee | 7 | 2020 | 366 | 2.630 |
Why?
| | Nociceptors | 5 | 2019 | 18 | 2.370 |
Why?
| | Arthritis, Experimental | 6 | 2020 | 139 | 2.340 |
Why?
| | Hyperalgesia | 5 | 2017 | 41 | 2.200 |
Why?
| | Ganglia, Spinal | 7 | 2020 | 47 | 2.070 |
Why?
| | Animals | 31 | 2020 | 5312 | 1.700 |
Why?
| | Immunity, Innate | 3 | 2020 | 97 | 1.570 |
Why?
| | Neurons | 3 | 2017 | 407 | 1.530 |
Why?
| | Disease Models, Animal | 16 | 2020 | 832 | 1.510 |
Why?
| | Mice | 19 | 2020 | 1894 | 1.370 |
Why?
| | Nerve Growth Factor | 2 | 2017 | 32 | 1.340 |
Why?
| | Chemokine CCL2 | 5 | 2018 | 25 | 1.220 |
Why?
| | Cartilage, Articular | 6 | 2018 | 586 | 1.210 |
Why?
| | Neuroimmunomodulation | 3 | 2020 | 11 | 1.210 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2014 | 60 | 1.180 |
Why?
| | Peptides | 3 | 2014 | 116 | 1.080 |
Why?
| | Nociception | 4 | 2019 | 9 | 0.990 |
Why?
| | Chronic Pain | 4 | 2020 | 102 | 0.930 |
Why?
| | Tissue Engineering | 2 | 2011 | 50 | 0.860 |
Why?
| | Receptors, CCR2 | 3 | 2017 | 8 | 0.830 |
Why?
| | Synovitis | 1 | 2019 | 22 | 0.810 |
Why?
| | Toll-Like Receptors | 1 | 2019 | 34 | 0.790 |
Why?
| | Disease Susceptibility | 1 | 2019 | 80 | 0.780 |
Why?
| | Pain Management | 2 | 2018 | 139 | 0.780 |
Why?
| | Gene Expression | 2 | 2020 | 272 | 0.770 |
Why?
| | Calcium | 3 | 2018 | 519 | 0.750 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 301 | 0.740 |
Why?
| | ADAM Proteins | 2 | 2015 | 95 | 0.720 |
Why?
| | Toll-Like Receptor 2 | 1 | 2018 | 36 | 0.710 |
Why?
| | Aggrecans | 2 | 2018 | 200 | 0.700 |
Why?
| | Cannabinoids | 1 | 2017 | 3 | 0.700 |
Why?
| | Phytotherapy | 1 | 2017 | 17 | 0.700 |
Why?
| | Cannabis | 1 | 2017 | 8 | 0.690 |
Why?
| | Clozapine | 1 | 2017 | 12 | 0.680 |
Why?
| | Neural Inhibition | 1 | 2017 | 9 | 0.680 |
Why?
| | Cytokines | 3 | 2019 | 364 | 0.680 |
Why?
| | Knee Joint | 3 | 2019 | 775 | 0.670 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 18 | 0.660 |
Why?
| | Behavior, Animal | 1 | 2017 | 113 | 0.630 |
Why?
| | Pain, Postoperative | 1 | 2020 | 306 | 0.610 |
Why?
| | Stifle | 1 | 2015 | 12 | 0.600 |
Why?
| | Antibodies, Neutralizing | 1 | 2015 | 26 | 0.600 |
Why?
| | Toll-Like Receptor 4 | 1 | 2015 | 32 | 0.600 |
Why?
| | Mice, Inbred C57BL | 8 | 2019 | 548 | 0.570 |
Why?
| | Tissue Scaffolds | 2 | 2011 | 27 | 0.560 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2011 | 42 | 0.560 |
Why?
| | Peptide Hydrolases | 1 | 2013 | 21 | 0.520 |
Why?
| | Joints | 1 | 2014 | 101 | 0.520 |
Why?
| | Protease Inhibitors | 1 | 2013 | 21 | 0.520 |
Why?
| | Menisci, Tibial | 4 | 2020 | 166 | 0.510 |
Why?
| | Mice, Knockout | 5 | 2018 | 399 | 0.480 |
Why?
| | Humans | 20 | 2020 | 31481 | 0.480 |
Why?
| | Drug Carriers | 1 | 2011 | 8 | 0.460 |
Why?
| | Blood Coagulation | 3 | 2006 | 28 | 0.460 |
Why?
| | Heparin | 2 | 2010 | 37 | 0.450 |
Why?
| | Chondroitin Sulfates | 1 | 2010 | 42 | 0.430 |
Why?
| | Orthopedic Procedures | 1 | 2014 | 322 | 0.430 |
Why?
| | Chondrogenesis | 1 | 2010 | 30 | 0.420 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2010 | 32 | 0.420 |
Why?
| | Male | 12 | 2020 | 17583 | 0.390 |
Why?
| | Plasma | 2 | 2006 | 36 | 0.380 |
Why?
| | Cells, Cultured | 4 | 2015 | 802 | 0.350 |
Why?
| | Fluorescent Antibody Technique | 2 | 2017 | 84 | 0.340 |
Why?
| | Disease Progression | 2 | 2020 | 861 | 0.310 |
Why?
| | Coated Materials, Biocompatible | 1 | 2006 | 41 | 0.300 |
Why?
| | RNA, Messenger | 2 | 2020 | 371 | 0.300 |
Why?
| | Models, Theoretical | 3 | 2020 | 112 | 0.280 |
Why?
| | Immunohistochemistry | 2 | 2017 | 494 | 0.280 |
Why?
| | Synovial Membrane | 2 | 2017 | 79 | 0.270 |
Why?
| | Hydrogels | 3 | 2014 | 9 | 0.260 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 378 | 0.260 |
Why?
| | Signal Transduction | 2 | 2019 | 588 | 0.250 |
Why?
| | Cattle | 3 | 2014 | 260 | 0.250 |
Why?
| | Analgesics | 2 | 2020 | 103 | 0.230 |
Why?
| | Chondrocytes | 2 | 2014 | 216 | 0.220 |
Why?
| | Bone Marrow Cells | 2 | 2011 | 63 | 0.220 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2020 | 6 | 0.220 |
Why?
| | Mice, Transgenic | 2 | 2018 | 308 | 0.210 |
Why?
| | Radiography | 2 | 2014 | 717 | 0.210 |
Why?
| | Microarray Analysis | 1 | 2020 | 12 | 0.210 |
Why?
| | Receptors, Pattern Recognition | 1 | 2019 | 5 | 0.210 |
Why?
| | Musculoskeletal Pain | 1 | 2020 | 19 | 0.210 |
Why?
| | Spinal Cord Dorsal Horn | 1 | 2019 | 9 | 0.200 |
Why?
| | Nerve Growth Factors | 1 | 2020 | 46 | 0.200 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 183 | 0.190 |
Why?
| | Phenotype | 1 | 2020 | 379 | 0.180 |
Why?
| | Ganglion Cysts | 1 | 2018 | 5 | 0.180 |
Why?
| | Matrix Metalloproteinases | 1 | 2018 | 31 | 0.180 |
Why?
| | Central Nervous System Sensitization | 1 | 2017 | 2 | 0.180 |
Why?
| | Dronabinol | 1 | 2017 | 1 | 0.180 |
Why?
| | Random Allocation | 2 | 2016 | 164 | 0.180 |
Why?
| | Cannabidiol | 1 | 2017 | 2 | 0.180 |
Why?
| | Receptors, CCR7 | 1 | 2017 | 7 | 0.180 |
Why?
| | Albuminuria | 1 | 2017 | 23 | 0.170 |
Why?
| | TRPC Cation Channels | 1 | 2017 | 25 | 0.170 |
Why?
| | NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 8 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2017 | 27 | 0.170 |
Why?
| | Catalysis | 3 | 2013 | 19 | 0.170 |
Why?
| | Chemokines, CC | 1 | 2017 | 8 | 0.170 |
Why?
| | Rats | 2 | 2018 | 966 | 0.170 |
Why?
| | Heparin-binding EGF-like Growth Factor | 2 | 2014 | 5 | 0.170 |
Why?
| | Osteonecrosis | 1 | 2017 | 19 | 0.170 |
Why?
| | Patch-Clamp Techniques | 1 | 2017 | 125 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 39 | 0.170 |
Why?
| | Chemokine CX3CL1 | 1 | 2016 | 2 | 0.160 |
Why?
| | Drug Design | 2 | 2014 | 34 | 0.160 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 494 | 0.160 |
Why?
| | Spinal Cord | 1 | 2017 | 99 | 0.160 |
Why?
| | Calgranulin A | 1 | 2015 | 4 | 0.150 |
Why?
| | alpha-Macroglobulins | 1 | 2015 | 12 | 0.150 |
Why?
| | Female | 5 | 2020 | 18253 | 0.150 |
Why?
| | Adsorption | 2 | 2014 | 6 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 136 | 0.150 |
Why?
| | Kidney Diseases | 1 | 2017 | 146 | 0.150 |
Why?
| | Proprotein Convertases | 1 | 2015 | 8 | 0.150 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 703 | 0.150 |
Why?
| | Serine Endopeptidases | 1 | 2015 | 19 | 0.150 |
Why?
| | Microglia | 1 | 2016 | 131 | 0.150 |
Why?
| | Pain Measurement | 1 | 2018 | 476 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 40 | 0.140 |
Why?
| | Horses | 1 | 2014 | 29 | 0.140 |
Why?
| | Dogs | 1 | 2014 | 283 | 0.140 |
Why?
| | Blood Pressure | 1 | 2015 | 260 | 0.130 |
Why?
| | Animals, Genetically Modified | 1 | 2013 | 18 | 0.130 |
Why?
| | Structure-Activity Relationship | 1 | 2013 | 54 | 0.130 |
Why?
| | Biotinylation | 1 | 2011 | 2 | 0.120 |
Why?
| | Fluorometry | 1 | 2011 | 5 | 0.120 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 719 | 0.120 |
Why?
| | Streptavidin | 1 | 2011 | 4 | 0.120 |
Why?
| | Tissue Culture Techniques | 1 | 2011 | 12 | 0.120 |
Why?
| | Solubility | 1 | 2011 | 39 | 0.120 |
Why?
| | Macrophages | 1 | 2012 | 129 | 0.110 |
Why?
| | Glycosaminoglycans | 1 | 2011 | 69 | 0.110 |
Why?
| | Protein Conformation | 1 | 2011 | 94 | 0.110 |
Why?
| | Stromal Cells | 1 | 2011 | 39 | 0.110 |
Why?
| | DNA | 1 | 2011 | 139 | 0.110 |
Why?
| | Kinetics | 1 | 2011 | 278 | 0.110 |
Why?
| | Polysaccharide-Lyases | 1 | 2010 | 5 | 0.110 |
Why?
| | Chondroitinases and Chondroitin Lyases | 1 | 2010 | 6 | 0.110 |
Why?
| | Heparitin Sulfate | 1 | 2010 | 8 | 0.110 |
Why?
| | Regeneration | 1 | 2010 | 30 | 0.110 |
Why?
| | Injections, Intra-Articular | 1 | 2010 | 81 | 0.100 |
Why?
| | Models, Animal | 1 | 2010 | 149 | 0.100 |
Why?
| | Dexamethasone | 1 | 2010 | 52 | 0.100 |
Why?
| | Rabbits | 1 | 2010 | 326 | 0.100 |
Why?
| | Proteoglycans | 1 | 2011 | 419 | 0.100 |
Why?
| | Surface Properties | 2 | 2006 | 139 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1273 | 0.090 |
Why?
| | Protein Engineering | 1 | 2008 | 6 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 59 | 0.090 |
Why?
| | Arthroscopy | 1 | 2014 | 781 | 0.080 |
Why?
| | Silanes | 1 | 2006 | 1 | 0.080 |
Why?
| | Microscopy, Atomic Force | 1 | 2006 | 10 | 0.080 |
Why?
| | Models, Biological | 2 | 2005 | 428 | 0.080 |
Why?
| | Mutation | 2 | 2020 | 464 | 0.080 |
Why?
| | Factor XII | 1 | 2005 | 1 | 0.080 |
Why?
| | Prothrombin | 1 | 2005 | 4 | 0.080 |
Why?
| | Coagulants | 1 | 2005 | 9 | 0.070 |
Why?
| | Biocompatible Materials | 1 | 2005 | 112 | 0.070 |
Why?
| | Collagen Type V | 1 | 2020 | 2 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 580 | 0.050 |
Why?
| | Skin | 1 | 2020 | 136 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2018 | 7 | 0.050 |
Why?
| | Sesquiterpenes, Guaiane | 1 | 2017 | 3 | 0.040 |
Why?
| | Piperidines | 1 | 2017 | 35 | 0.040 |
Why?
| | Indoles | 1 | 2017 | 58 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 138 | 0.040 |
Why?
| | Models, Anatomic | 1 | 2016 | 68 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 191 | 0.040 |
Why?
| | Reference Values | 1 | 2016 | 260 | 0.040 |
Why?
| | Cricetinae | 1 | 2015 | 52 | 0.040 |
Why?
| | Podocytes | 1 | 2017 | 171 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2015 | 89 | 0.040 |
Why?
| | Crystallization | 1 | 2014 | 6 | 0.040 |
Why?
| | Epitopes | 1 | 2015 | 92 | 0.040 |
Why?
| | Diffusion | 1 | 2014 | 28 | 0.040 |
Why?
| | Cell Survival | 1 | 2014 | 181 | 0.030 |
Why?
| | Materials Testing | 1 | 2014 | 140 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2014 | 295 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2014 | 232 | 0.030 |
Why?
| | Hypertension | 1 | 2015 | 283 | 0.030 |
Why?
| | 3T3 Cells | 1 | 2008 | 19 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 35 | 0.020 |
Why?
| | Binding Sites | 1 | 2008 | 93 | 0.020 |
Why?
| | Protein Binding | 1 | 2008 | 155 | 0.020 |
Why?
| | Brain | 1 | 2017 | 1655 | 0.020 |
Why?
| | Factor XIIa | 1 | 2005 | 1 | 0.020 |
Why?
| | Titrimetry | 1 | 2005 | 4 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2005 | 14 | 0.020 |
Why?
| | Thrombin | 1 | 2005 | 14 | 0.020 |
Why?
| | Blood Platelets | 1 | 2005 | 52 | 0.020 |
Why?
| | Blood Coagulation Factors | 1 | 2005 | 19 | 0.020 |
Why?
| | Models, Statistical | 1 | 2005 | 144 | 0.020 |
Why?
| | Adult | 1 | 2017 | 9779 | 0.020 |
Why?
| | Aged | 1 | 2017 | 10295 | 0.020 |
Why?
| | Middle Aged | 1 | 2017 | 11209 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 1902 | 0.010 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|